January 6, 2014

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2014 ACS

Patent Number: WO 2013177349
Title: Preparation of quinazolinediones as tankyrase inhibitors for the treatment of cancer
Inventor(s): Keenan, Richard M.; Miller, Aaron Bayne; Qin, Donghui
Patent Assignee(s): GlaxoSmithKline LLC, USA
Source: PCT Int. Appl., 81pp. CODEN: PIXXD2
Language: English

Abstract:
The invention relates to quinazolinediones of formula I and their prepn., useful as modulators, notably inhibitors, of tankyrases (TNKS1 and TNKS2) in the treatment of cancer, fibrosis, and other hyperproliferative diseases.  Compds. of formula I, in which R1, R2, and R3 are independently H, halo, C1-4 alkyl, and C1-4 alkoxy, provided that at least one of R1, R2, and R3 is not H; R4 is H and Me; or pharmaceutically acceptable salts thereof, are claimed.  Example compd. II was prepd. by a multistep process (procedure given).  Invention compds. were evaluated for the tankyrase inhibitory activity.  From the assay, it was detd. that II exhibited pIC50 values of 8.1 (TNKS1) and 7.1 (TNKS2).

Please note:  Abstracts and Titles for patent records in CAplus are routinely enhanced to better describe the claimed invention.

 View the full-text here.

Recent News

       
    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value
    
    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    Professionals
    
    January 26, 2015
 | Annual MEDLINE Reload on STN
    Features Enhanced Clinical Trial Information and the
    2015 MeSH Thesaurus
                               
  
                                                                     More News >> 

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624                                       
 Email: cas-pr@cas.org